Table 2. Relationship between TGFBI expression and clinicopathological features of NSCLC patients.
|
NSCLC (n=364) |
ADC (n=242) |
SCC (n=122) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
n
(%) |
|
n
(%) |
|
n
(%) |
|
||||
| Low | High | P | Low | High | P | Low | High | P | |
|
Age | |||||||||
| ⩽70 | 107 (59.8) | 72 (40.2) | 0.284 | 71 (43.8) | 91 (56.2) | 0.146 | 37 (56.1) | 29 (43.9) | 0.692 |
| >70 |
121 (65.4) |
64 (34.6) |
|
43 (53.7) |
37 (46.3) |
|
29 (51.8) |
27 (48.2) |
|
|
Gender | |||||||||
| Male | 91 (51.7) | 85 (48.3) | 0.405 | 49 (48) | 53 (52) | 0.804 | 42 (56.8) | 32 (43.2) | 0.464 |
| Female |
89 (47.3) |
99 (52.7) |
|
65 (46.4) |
75 (53.6) |
|
24 (50) |
24 (50) |
|
|
Stage | |||||||||
| I–II | 136 (47.2) | 152 (52.8) | 0.098 | 89 (46.6) | 102 (53.4) | 0.758 | 47 (48.5) | 50 (51.5) | 0.014 |
| III–IV |
44 (57.9) |
32 (42.1) |
|
25 (49) |
26 (51) |
|
19 (76) |
6 (24) |
|
|
pT | |||||||||
| T1 | 63 (46) | 74 (54) | 0.304 | 41 (41.8) | 57 (58.2) | 0.175 | 22 (56.4) | 17 (43.6) | 0.725 |
| T2/T3/T4 |
117 (51.5) |
110 (48.5) |
|
73 (50.7) |
71 (49.3) |
|
44 (53) |
39 (47) |
|
|
pN | |||||||||
| N0 | 124 (47.1) | 139 (52.9) | 0.156 | 88 (47.6) | 97 (52.4) | 0.796 | 36 (46.2) | 42 (53.8) | 0.019 |
| N1–N2–N3 |
56 (55.4) |
45 (44.6) |
|
26 (45.6) |
31 (54.4) |
|
30 (68.2) |
14 (31.8) |
|
|
Histology | |||||||||
| ADC | 114 (80.3) | 128 (19.7) | 0.208 | ||||||
| SCC |
66 (54.1) |
56 (45.9) |
|
|
|
|
|
|
|
|
Smoking statusa | |||||||||
| Never | 22 (57.9) | 16 (42.1) | 0.204 | 22 (57.9) | 16 (42.1) | 0.021 | — | — | 0.496 |
| Former | 90 (52.6) | 81 (47.4) | 58 (52.7) | 52 (47.3) | 32 (52.5) | 29 (47.5) | |||
| Current | 68 (44.2) | 86 (55.8) | 34 (36.2) | 60 (63.8) | 34 (56.7) | 26 (43.3) | |||
Abbreviations: ADC=adenocarcinoma; NSCLC=non-small cell lung cancer; pN=pathological N stage; pT=pathological T stage; SCC=squamous cell carcinoma.
a
Smoking status data were available for n=363 patients. The values highlighted in bold are statistically significant (P<0.05).